Ryan Fukushima Sells 23,818 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 23,818 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $46.19, for a total value of $1,100,153.42. Following the completion of the sale, the chief executive officer directly owned 143,945 shares of the company’s stock, valued at $6,648,819.55. This trade represents a 14.20% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Fukushima also recently made the following trade(s):

• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The stock was sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total value of $600,000.00.
• On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total transaction of $597,148.50.

Tempus AI Stock Performance

Shares of TEM stock opened at $46.12 on Friday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a fifty day simple moving average of $51.29 and a two-hundred day simple moving average of $51.95. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32. The firm has a market capitalization of $8.28 billion, a PE ratio of -32.03 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.22) earnings per share. Analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on TEM shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Wolfe Research began coverage on Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. BTIG Research decreased their price target on Tempus AI from $80.00 to $70.00 and set a “buy” rating for the company in a report on Monday. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research note on Friday, July 31st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Nine equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average target price of $64.92.

Institutional Trading of Tempus AI

Several hedge funds have recently added to or reduced their stakes in TEM. JPL Wealth Management LLC bought a new stake in shares of Tempus AI during the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI in the 3rd quarter valued at about $38,000. Whittier Trust Co. grew its holdings in shares of Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its position in shares of Tempus AI by 88.8% in the second quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock worth $44,000 after purchasing an additional 325 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.